Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chmp symbols : Abbv save search
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-07-21 (Crawled : 09:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
tepkinly abbvie chmp positive treatment
AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Published: 2023-06-23 (Crawled : 12:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.08%
H: 1.01%
C: -1.01%
abbvie chmp positive treatment migraine
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published: 2023-02-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
rinvoq treatment disease abbvie chmp positive
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published: 2022-09-19 (Crawled : 08:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.29%
H: 0.15%
C: -0.68%
skyrizi treatment disease chmp risankizumab positive
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
rinvoq treatment active chmp approval
CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
Published: 2022-05-23 (Crawled : 07:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
rinvoq treatment chmp approval ulcerative colitis
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
Published: 2021-10-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.22%
H: 0.74%
C: 0.16%
treatment europe positive risankizumab chmp
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Published: 2021-04-23 (Crawled : 14:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.31%
H: 1.88%
C: 1.52%
myeloid leukemia positive therapy leukemia chmp acute myeloid leukemia
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Published: 2020-12-11 (Crawled : 13:13) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.45%
H: 0.38%
C: -0.63%
approval treatment chmp
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.